title: Scar-mediated inhibition and CSPG receptors in the CNS.
abstract: Severed axons in adult mammals do not regenerate appreciably after central nervous system (CNS) injury due to developmentally determined reductions in neuron-intrinsic growth capacity and extracellular environment for axon elongation. Chondroitin sulfate proteoglycans (CSPGs), which are generated by reactive scar tissues, are particularly potent contributors to the growth-limiting environment in mature CNS. Thus, surmounting the strong inhibition by CSPG-rich scar is an important therapeutic goal for achieving functional recovery after CNS injuries. As of now, the main in vivo approach to overcoming inhibition by CSPGs is enzymatic digestion with locally applied chondroitinase ABC (ChABC), but several disadvantages may prevent using this bacterial enzyme as a therapeutic option for patients. A better understanding of the molecular mechanisms underlying CSPG action is needed in order to develop more effective therapies to overcome CSPG-mediated inhibition of axon regeneration and/or sprouting. Because of their large size and dense negative charges, CSPGs were thought to act by non-specifically hindering the binding of matrix molecules to their cell surface receptors through steric interactions. Although this may be true, recent studies indicate that two members of the leukocyte common antigen related (LAR) phosphatase subfamily, protein tyrosine phosphatase σ (PTPσ) and LAR, are functional receptors that bind CSPGs with high affinity and mediate CSPG inhibitory effects. CSPGs also may act by binding to two receptors for myelin-associated growth inhibitors, Nogo receptors 1 and 3 (NgR1 and NgR3). If confirmed, it would suggest that CSPGs have multiple mechanisms by which they inhibit axon growth, making them especially potent and difficult therapeutic targets. Identification of CSPG receptors is not only important for understanding the scar-mediated growth suppression, but also for developing novel and selective therapies to promote axon sprouting and/or regeneration after CNS injuries, including spinal cord injury (SCI).
authors: Department of Neurology, UT Southwestern Medical Center, Dallas, TX 75390-8813, USA.
authors: Kartavya
authors: K
authors: Sharma
authors: Michael E
authors: ME
authors: Selzer
authors: Shuxin
authors: S
authors: Li
mesh_terms: D000818:Animals; D019765:Chondroitin ABC Lyase / Q000378:metabolism; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D002921:Cicatrix / Q000378:metabolism*; D006801:Humans; D009416:Nerve Regeneration / Q000502:physiology*; D011956:Receptors, Cell Surface / Q000378:metabolism*; D013119:Spinal Cord Injuries / Q000378:metabolism*
chemical_list: D011508:Chondroitin Sulfate Proteoglycans; D011956:Receptors, Cell Surface; C487486:chondroitin sulfate proteoglycan receptor, human; D019765:Chondroitin ABC Lyase